Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

(2019) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab: from scientific evidence to clinical practice—the first Italian real-life data

(2019) Piero Barbanti et al.   NEUROLOGICAL SCIENCES

A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody

(2019) William Kielbasa et al.   CEPHALALGIA

Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal

(2018) A. P. Andreou et al.   EUROPEAN JOURNAL OF NEUROLOGY

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention

(2018) Vladimir Skljarevski et al.   JAMA Neurology

Galcanezumab in chronic migraine

(2018) Holland C. Detke et al.   NEUROLOGY

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Hong Sun et al.   LANCET NEUROLOGY

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

(2014) David W Dodick et al.   LANCET NEUROLOGY